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Abstract 
 Aluminum adjuvants have been used in vaccines for over 80 years in order to 
increase the immune response in vaccinated individuals. While the addition of aluminum 
adjuvants has been extremely successful, the success powered the adjuvants to be 
used in numerous vaccines without a proper understanding of their mechanisms of 
action. Advancements in medical understanding over the last 4-5 decades has resulted 
in researchers understanding the harsh reality of aluminum toxicity. Due to this, 
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researchers have begun to delve into the actions and mechanisms of these adjuvants in 
an effort to enhance understanding of how they work. This review will discuss the 
importance of understanding the history of vaccination, the use and incredible success 
of aluminum adjuvants in vaccines, proposed mechanisms of action for aluminum 
adjuvants, aluminum toxicity levels, and future issues to be discussed regarding the 
safety of addition of aluminum adjuvants. 
Keywords 
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Introduction 
The theory and practicality of vaccination has existed for centuries but has only 
recently come to full power near the turn of the 20th century. Vaccinations have been 
used to eradicate deadly infectious diseases such as smallpox and decrease overall 
mortality in the United States, “from 797 deaths per 100,000 in 1900 to 36 deaths per 
100,000 in 1980” (Armstrong, Conn, & Pinner, 1999). However, in the 21st century, 
vaccination practices have come under attack due to a controversial article published in 
1998 by Dr. Andrew Wakefield of the United Kingdom that proposed a link between the 
MMR (Measles, Mumps, and Rubella) vaccination and autism (Wakefield, et al., 1998). 
This article was picked up by media outlets across the globe, leading to a decrease in 
early childhood MMR vaccination in the United Kingdom, with rates decreasing from 90-
95% in 1995-96, to roughly 80% in 2003-04 (Thompson, 2009). While 21 years have 
passed since the publication – during which Dr. Wakefield was removed from the United 
Kingdom Medical Register, the publication was recanted, and all the claims of the 
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publication were discredited – there remains an atmosphere of distrust involving 
vaccinations. 
Many believed then and still do today that Wakefield’s contains some truth, and 
the general media played an important role in swaying the public’s mentality towards the 
dangers of vaccines. Due to this, the United Kingdom saw a decrease in the number of 
children getting MMR vaccinations, decreasing from 91.8% coverage in 1995-96 to 
79.9% coverage in 2003-04 (Screening & Immunisations Team, NHS Digital, 2017) 
(Thompson, 2009). In recent years, researchers have become more interested in the 
mechanism of action for licensed aluminum-based adjuvants used in vaccines. 
Despite the growing trend of “Anti-vaccination” throughout the United States, 
there appears to be gaps in the literature that indicate the true mechanism of action for 
aluminum vaccine adjuvants, which is coincidentally a major focal point of the anti-
vaccination movement. There has been a great deal of literature published on aluminum 
adjuvants and their relative safety, but it seems that there is no agreement on the true 
mechanism of action for aluminum-based adjuvants. It is important that countries which 
strongly promote the use of vaccines understand the necessity of aluminum adjuvants 
and improve the quality and quantity of research regarding aluminum vaccine adjuvants. 
In this review, the results of several studies regarding the proposed mechanisms 
of action of aluminum adjuvants, regulation of production for vaccines, the implications 
of declining numbers of vaccinated individuals, and the importance of the government’s 
role in vaccination schedule requirements are discussed. This information is 
corroborated with data published by the United States government via the Centers for 
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Disease Control and Prevention. This discussion revolves around 4 key questions that 
will help to understand the importance and limitations of vaccinations: 1) what is the 
origin and history of vaccinations; 2) why are aluminum salts used as adjuvants in 
vaccines; 3) why are some individuals unable to be vaccinated; and 4) what is “herd 
immunity” and what role does it play in modern disease control. Identification of the true 
mechanism of action for aluminum salt adjuvants may increase vaccination rates, 
effectively reducing the recent outbreaks of communicable diseases such as measles 
(Centers for Disease Control and Prevention, 2019).  
Deadly Smallpox and the Origin of Vaccination 
 The origins of disease traverse well beyond the time of written history. It is likely 
that humans have experienced infectious diseases since their delineation from their 
most recent common ancestor. One such infectious disease, estimated to be around 
since 10,000 B.C. is known as smallpox (Reidel, 2005). By the 18th century, smallpox 
was spreading to Europe, causing an estimated 6-10% of all deaths in London as 
reported by Davenport et al (Davenport et al, 2011). The first attempts at an early form 
of vaccination was called inoculation. Inoculation is the practice of introducing a live, 
infectious organism into a host in order to confer immunity upon contraction and after 
recovering from said infection. This practice was widely used throughout Europe in the 
late 18th century. 
 By the late 18th century, a man by the name of Edward Jenner had published his 
own findings that suggested inoculation with cowpox – a common disease amongst 
dairy maids at the time – may confer immunity to smallpox. Jenner administered several 
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inoculations of cowpox excretions from infected individuals into healthy individuals. He 
found that these individuals would contract cowpox but would later recover. Once the 
individuals had recovered, Jenner would inoculate them with smallpox. Just as he 
suspected, these individuals had become immune to smallpox. Jenner named his 
technique vaccination. While his practices were met with controversy and distrust, years 
would pass, and Jenner’s technique would eventually make its way back to Europe and 
the United States of America. Jenner became the first individual to recognize the 
scientific evidence behind vaccination, and his technique would be carried on for over a 
century, as scientists worked to develop new and safer vaccination techniques. 
 Louis Pasteur, a French scientist, would be one of the first to extend Jenner’s 
work, creating the first attenuated vaccine. It was Pasteur who found that by growing a 
virulent strain of bacteria at an unusually high temperature would render the bacteria 
avirulent. He found that inoculating animals with the avirulent strain of the bacteria 
would result in the animal being immune to a virulent strain. This led to the development 
of the anthrax vaccine by Pasteur himself. 
 Years later, in the 1950s, a motion was set forward by the World Health 
Organization that promoted the use of vaccination against smallpox across the globe. 
By 1977, smallpox was eradicated completely from the world. While Jenner’s 
experiments into vaccination may not have earned him copious recognition during his 
lifetime, it is now recognized that without his work, the world could very well still suffer 
from the epidemics caused by innumerable deadly diseases that are commonly 
vaccinated against today. 
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Antibody-Mediated Immunity Provides Long-Term Immunity 
 Adaptive immunity is that which is procured by introduction of an antigen to an 
organism. An antigen is defined as a foreign substance that induces an inflammatory 
response. Antigens may be bacterial DNA, lipopolysaccharides of bacterial cells, viral 
capsid proteins, or even foreign particles introduced to the body such as chemical 
compounds. In order to provide clarity and conciseness, a brief and basic 
summarization of basic adaptive immunity is as follows: Adaptive immunity is mediated 
by proteins called immunoglobulins, or antibodies, which are produced by B cells. Upon 
introduction of an antigen, antigen-processing cells called dendritic cells may 
phagocytize the antigen, use peptidases to fragment the antigen, and present the 
fragments of antigen attached to MHC class II receptor molecules on the cell surface. 
 Once presented on the cell surface, Helper T cells are presented with the 
antigen, and they in turn secrete cytokines that initiate maturation of naïve B cells. Upon 
maturation, B cells produce antibodies which attach themselves to the antigen, allowing 
the body to locate these antibodies and recognize the antigen as a foreign particle. 
Following secondary stimulation of B cells with the same antigen and cytokine 
secretion, the immune system will be able to quickly recognize a second encounter with 
the foreign particle and quickly remove it via phagocytosis and lysosomal fragmentation. 
This memory mechanism is likely related to the ability of T cells to signal B cells in 
exactly the same way as they had on the first encounter, therefore resulting in the same 




 Secondary immune responses typically result in a faster response and increased 
levels of antigen-specific antibodies, which are maintained in the bloodstream for a 
prolonged period of time. Due to this action, a secondary immunization is typical for 
most vaccines, because resultant blood-antibody levels will confer immunity for a longer 
period of time in humans and animals. 
Aluminum Adjuvants in Vaccines Increases Immune Response 
 As previously discussed, Edward Jenner is considered to be the father of 
vaccination. His work provided insights into the actions of human humoral immunity, 
further progressing the understanding of immunology. While his practices may have 
prevented the deaths of hundreds of thousands of people, his technique still held an 
inherent risk of death to those who did not develop immunity to smallpox and to those 
who did not receive a second vaccination in their later years. Due to this, scientists 
began to delve into the science behind vaccination and the actions of the human 
immune system in order to develop vaccinations that ensured development of immunity. 
 By the early 1900s, tetanus and diphtheria toxins had become a subject of great 
concern when it was found that New York City alone averaged 14,000 cases of 
diphtheria and 1,290 deaths per year from the diphtheria toxin (Marrack, McKee, & 
Munks, 2009). Scientists began to formulate ways to increase the efficacy of 
vaccinations by adding antibodies and toxins together to form what was known as toxin-
antitoxin vaccinations. These vaccinations were highly regarded due to their ability to 
initiate an immune response with greater protection and decreased adverse effects from 
the vaccination. By 1921, scientists had developed a new, heat-killed form of the 
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diphtheria toxin called the toxoid. By heating the toxin, it was found that it would be 
inactivated but would still initiate an immune response in the vaccinated individual. This 
proved to be the best defense against the toxins during the time period. In 1926, 
Alexander T. Glenny found that precipitating an antigen onto insoluble particles of 
aluminum potassium sulfate would result in an increased level of antibody response. 
This discovery would eventually lead to the worldwide use of aluminum salts in nearly 
all vaccines. When the practice of aluminum salt addition to vaccines first began, there 
was very little interest in the mechanisms of action for the longevity of immunity seen 
with these new adjuvants. In recent years, however, scientists have attempted to study 
the mechanism of action for licensed aluminum adjuvants, but there seems to be little 
agreement within the community about the true mechanism of action. These studies 
have helped to understand the actions of aluminum adjuvants and their role in 
increased immune response after vaccination, as well as defining the generalized 
mechanisms of the human immune system. 
Proposed Mechanisms of Action for Aluminum Adjuvants 
While still poorly understood, there have been several mechanisms of action 
proposed for aluminum adjuvants. The first example of a proposed mechanism is the 
depot effect, proposed by Glenny et al in 1926 (Gupta, Rost, Relyveld, & Siber, 1995). 
This mechanistic explanation purports that, due to its insoluble nature, the aluminum 
salts are maintained in the area of injection for a prolonged period of time, allowing for 
maximal contact with the antigen. This gives the immune system ample time to develop 
antibodies against the antigen and promote phagocytosis and lysosomal digestion. 
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A second proposed mechanism asserts that aluminum salts promote 
inflammation, resulting in an increased recruitment of immunocompetent cells to the site 
of injection, and ultimately the development of antibodies against the antigen. 
A third mechanism that has been proposed is the “promotion of uptake of 
antigens by antigen-presenting cells” (Rambe, Giudice, Rossi, & Sanicas, 2015). This 
mechanism of action proposes that the aluminum salts induce a localized inflammatory 
response, resulting in increased uptake of antigen by antigen-presenting cells. This 
begins the series of events mentioned in the previous mechanism, ultimately resulting in 
conferred immunity. 
While these three mechanisms have been researched extensively, there is still 
little to no agreement as to which is the true mechanism, and the possibility of these 
three mechanisms working synergistically still remains unmentioned in the literature. 
Vaccine Regulation 
 Vaccines are heavily regulated and must undergo extreme scrutiny before they 
are able to be used on the general public. The governing bodies that oversee the 
regulations are a mixture of international bodies, as well as national and state 
governments. While the international and national governing bodies oversee the safety 
and efficacy of each and every vaccine, the state governing bodies dictate which 
vaccines are to be used within their specific area. 
 The United States federal government uses extreme scrutiny when studying the 
safety and efficacy of vaccinations. The Food and Drug Administration (FDA) is the 
primary body that oversees the trials of vaccines before they are approved and released 
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for use on the general public. According to the Centers for Disease Control and 
Prevention, there are 6 major steps that a vaccine must go through in order to be 
approved for full use in the United States. First the vaccine must go through the 
exploratory stage, where the researchers study multiple different antigens to find which 
may be used in a vaccine to control preventable diseases. This stage can last up to 4 
years, during which the federal government funds the research. Once the research 
proves to have developed a proper antigen that can initiate an immune response, the 
vaccine moves on to the pre-clinical trials. 
 The pre-clinical trials consist of animal testing, as well as tissue and cell cultures 
to help understand the body’s response to the given vaccine. During this phase, the 
researchers may adjust the concentration of antigen in the vaccine to ensure adequate 
dosage without increased risk of infection. Very few potential vaccines continue beyond 
this state due to their inadequacies. This stage is reported to last up to 2 years. Once 
approved beyond the pre-clinical phase of investigation, the vaccine will move on to 
privatized manufacturing. 
 During the period of privatized manufacturing, a company will adopt the vaccine 
and propose manufacturing methods to the FDA, which will either deny or approve the 
methods. These methods must pass through several review boards including a clinical 
review board, which must approve the proposed process for clinical trials, which are 
conducted at a specific institution. After the approval process is complete, the vaccine is 
then progressed to three testing phases which will dictate their safety and efficacy. 
 The first phase of vaccine trials takes place with a small group of less than 100 
adults. The goal of phase I trials is to assess the vaccine’s viability in initiating an 
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immune response, and the length of time that the immune response is instigated. If the 
vaccine instigates a proper response, the researchers may attempt to infect some of the 
individuals with the disease under close monitoring and control. Upon completion of 
phase I, the vaccine will be evaluated and will either progress to phase II or be removed 
from testing. 
 During phase II trials, the vaccine is given to individuals who are at risk for 
developing the disease that the vaccine is meant to prevent. In these trials, a placebo 
group is used to estimate the true efficacy of the vaccine. This phase also gives the 
researchers insight into the effects of the vaccine when given to a participant who is at 
risk for acquiring the disease. During phase II, several other factors are proposed, 
including the dosage of the vaccine, the method of delivery for the vaccine, and the 
proper immunization schedule for the vaccine. Upon successful completion and 
evaluation, the candidate vaccine will move on to Phase III trials. 
 Phase III trials involve administration of the vaccine to thousands of people. 
These trials test the vaccine against a placebo. Due to the large population involved in 
this phase, the adverse effects of the vaccine may also be studied as well. This gives 
the researchers insight into their product’s safety on a large scale, and it also helps to 
define the efficacy of the vaccine. This phase also shows any low-risk adverse effects 
on individuals. Upon completion of phase III testing, the manufacture must submit a 
license application to be approved by the FDA. After approval, the vaccine’s production 
is continuously inspected and monitored by the FDA, including data analysis, safety 
analysis, and facility inspections. 
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 The entire process of vaccine approval and use on the general public may take a 
decade or longer, which emphasizes the United States’ role in regulating vaccine 
production. The safety of a vaccine is taken very seriously and any proven implication 
that the vaccine may incur serious adverse effects could result in its removal from the 
vaccination schedule. Beyond the federal government’s involvement in vaccine 
regulation, the states also have the decision to require certain vaccines before enrolling 
in an educational institution so long as these requirements do not overreach the federal 
government’s standards. This may include requiring all children above a certain age to 
have acquired all necessary and/or recommended vaccines pertaining to that age group 
before they enroll into the institution. States may also opt out of requiring certain 
vaccines before enrollment, so long as these do not overstep the requirements of the 
federal government. 
Importance of Vaccination Schedule 
 While vaccination in itself is important in preventing a large majority of 
communicable diseases, it is equally important to pursue proper vaccination schedule. 
As stated previously, vaccines are not 100% effective, and several require two, three, 
and even four administrations in order to elicit maximal immunity. According to the CDC, 
the current 2019 schedule recommends that children aged from birth to 5 months 
receive 3 doses of the Hepatitis B vaccine, 2 doses of the Rotavirus vaccine, 4 doses of 
the DTaP vaccine, 3-4 doses of Haemophilus influenzae type b, 4 doses of 
Pneumococcal conjugate, 3 doses of Inactivated Poliovirus, and 1-2 doses annually of 
the influenza vaccine. These specific vaccines only confer maximal immunity upon 
administration of the final dose of each vaccine. Consequently, some variations of 
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several of the previously-mentioned vaccines contain aluminum adjuvants. While there 
may currently be a distrust of vaccines containing additives such as aluminum salts, it is 
strongly recommended that children are vaccinated against these diseases, as they can 
prove fatal if contracted. 
 A proper vaccination schedule also helps to prevent the transmission of 
communicable diseases to those who are unable to be vaccinated due to health risks 
associated with infection and compromised immunity. Recently, this has come to be 
known as “herd immunity,” and has proved successful over the last several decades. 
Herd immunity occurs when a large enough number of individuals are vaccinated 
against a given disease, therefore preventing the disease from spreading person-to-
person. With such a large amount of people who are unable to contract the disease, 
those individuals who are unable to be vaccinated due to health concerns are also 
considered immune because they are at a decreased risk of coming into contact with 
someone who has the disease. 
Summary 
 While there has been an abundance of advancements in understanding the 
mechanisms of aluminum adjuvants and their biological fates, there is still a great deal 
of research to be done on them. As reported in this review, there has been a drastic 
decline in vaccinations in the United Kingdom, as well as a developed anti-vaccination 
movement found in the United States. The development of this movement is likely the 
result of declining trust in vaccinations due to poor understanding of mechanism of 
action of aluminum adjuvant constituents. In future studies, researchers should focus on 
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a singular proposed mechanism of action and report findings that either demonstrate 
truth of a single mechanism or falsify another mechanism. By increasing our 
understanding of these adjuvants, we can further the great success of vaccination by 
providing the media, the public, and medical professionals with a genuine knowledge of 
the true mechanism of action of vaccines containing aluminum adjuvants. 
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